Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025
Iridex (NASDAQ:IRIX) has released preliminary Q1 2025 financial results, showing signs of business stabilization. The company expects total revenue between $11.8-12.0 million, comparable to Q1 2024's $11.8 million.
Key operational metrics include sales of approximately 13,900 Cyclo G6 probes (up from 13,300 year-over-year) and 24 Cyclo G6 Laser Systems (up from 22). Cash and cash equivalents stood at $7.2 million as of March 29, 2025.
The company reports improved financial condition following strategic investment from Novel Inspiration International Co., , with consecutive quarterly revenue increases while reducing operating expenses. Management indicates potential for breakeven or better performance at historical revenue levels, despite exposure to external factors like tariff policy changes.
Iridex (NASDAQ:IRIX) ha pubblicato i risultati finanziari preliminari del primo trimestre 2025, mostrando segnali di stabilizzazione dell’attività. L’azienda prevede un fatturato totale compreso tra 11,8 e 12,0 milioni di dollari, in linea con gli 11,8 milioni di dollari registrati nel primo trimestre 2024.
I principali indicatori operativi includono vendite di circa 13.900 sonde Cyclo G6 (in aumento rispetto alle 13.300 dell’anno precedente) e 24 sistemi laser Cyclo G6 (in crescita rispetto a 22). La liquidità e le equivalenti ammontano a 7,2 milioni di dollari al 29 marzo 2025.
L’azienda segnala un miglioramento della situazione finanziaria a seguito di un investimento strategico da parte di Novel Inspiration International Co., con incrementi consecutivi del fatturato trimestrale e una riduzione delle spese operative. Il management indica la possibilità di raggiungere il pareggio o risultati migliori ai livelli di fatturato storici, nonostante l’esposizione a fattori esterni come le variazioni delle politiche tariffarie.
Iridex (NASDAQ:IRIX) ha publicado resultados financieros preliminares del primer trimestre de 2025, mostrando señales de estabilización del negocio. La compañía espera ingresos totales entre 11,8 y 12,0 millones de dólares, comparables a los 11,8 millones de dólares del primer trimestre de 2024.
Las métricas operativas clave incluyen ventas de aproximadamente 13,900 sondas Cyclo G6 (un aumento respecto a las 13,300 del año anterior) y 24 sistemas láser Cyclo G6 (subiendo desde 22). El efectivo y equivalentes de efectivo se situaron en 7,2 millones de dólares al 29 de marzo de 2025.
La compañía informa una mejoría en su condición financiera tras una inversión estratégica de Novel Inspiration International Co., con incrementos consecutivos en los ingresos trimestrales y reducción de gastos operativos. La dirección indica potencial para alcanzar el punto de equilibrio o un mejor desempeño en niveles históricos de ingresos, a pesar de la exposición a factores externos como cambios en la política arancelaria.
Iridex (NASDAQ:IRIX)는 2025년 1분기 잠정 재무 실적을 발표하며 사업 안정화 조짐을 보였습니다. 회사는 총 매출이 1,180만~1,200만 달러로 2024년 1분기 1,180만 달러와 비슷할 것으로 예상합니다.
주요 운영 지표로는 약 13,900대의 Cyclo G6 프로브 판매(전년 동기 대비 13,300대에서 증가)와 24대의 Cyclo G6 레이저 시스템 판매(22대에서 증가)가 포함됩니다. 2025년 3월 29일 기준 현금 및 현금성 자산은 720만 달러였습니다.
회사는 Novel Inspiration International Co.의 전략적 투자 이후 재무 상태가 개선되었으며, 분기별 매출이 연속 증가하고 운영비용은 감소했다고 보고합니다. 경영진은 관세 정책 변화와 같은 외부 요인에 노출되어 있음에도 불구하고 과거 매출 수준에서 손익분기점 도달 또는 그 이상의 성과 가능성을 시사합니다.
Iridex (NASDAQ:IRIX) a publié ses résultats financiers préliminaires du premier trimestre 2025, montrant des signes de stabilisation de l’activité. La société prévoit un chiffre d’affaires total compris entre 11,8 et 12,0 millions de dollars, comparable aux 11,8 millions de dollars du premier trimestre 2024.
Les indicateurs opérationnels clés incluent la vente d’environ 13 900 sondes Cyclo G6 (en hausse par rapport à 13 300 un an plus tôt) et 24 systèmes laser Cyclo G6 (contre 22 auparavant). La trésorerie et les équivalents de trésorerie s’élevaient à 7,2 millions de dollars au 29 mars 2025.
La société rapporte une amélioration de sa situation financière suite à un investissement stratégique de Novel Inspiration International Co., avec des augmentations consécutives du chiffre d’affaires trimestriel tout en réduisant les dépenses d’exploitation. La direction indique un potentiel d’atteindre le seuil de rentabilité ou mieux à des niveaux de chiffre d’affaires historiques, malgré une exposition à des facteurs externes tels que les changements de politique tarifaire.
Iridex (NASDAQ:IRIX) hat vorläufige Finanzergebnisse für das erste Quartal 2025 veröffentlicht, die Anzeichen einer Geschäfts-Stabilisierung zeigen. Das Unternehmen erwartet einen Gesamtumsatz zwischen 11,8 und 12,0 Millionen US-Dollar, vergleichbar mit 11,8 Millionen US-Dollar im ersten Quartal 2024.
Zu den wichtigsten operativen Kennzahlen gehören der Verkauf von etwa 13.900 Cyclo G6 Sonden (ein Anstieg gegenüber 13.300 im Vorjahreszeitraum) sowie 24 Cyclo G6 Lasersysteme (vorher 22). Die liquiden Mittel beliefen sich zum 29. März 2025 auf 7,2 Millionen US-Dollar.
Das Unternehmen berichtet von einer verbesserten Finanzlage nach einer strategischen Investition von Novel Inspiration International Co., mit aufeinanderfolgenden Umsatzsteigerungen im Quartal und gleichzeitiger Senkung der Betriebskosten. Das Management sieht die Möglichkeit, bei historischen Umsatzniveaus die Gewinnschwelle zu erreichen oder zu übertreffen, trotz der Einflüsse externer Faktoren wie Änderungen der Zollpolitik.
- Revenue growth expected at $11.8-12.0M, showing stabilization
- 4.5% increase in Cyclo G6 probe sales to 13,900 units
- 9.1% increase in Cyclo G6 Laser Systems sales to 24 units
- Significant reduction in operating expenses
- Strategic investment from Novel Inspiration strengthening financial position
- Minimal revenue growth compared to Q1 2024 ($11.8M)
- Exposure to external risks from tariff policy changes
- Cash position of $7.2M may require additional funding
- Results still subject to auditor review and potential adjustments
Insights
Iridex's Q1 2025 preliminary results signal modest operational progress amid ongoing stabilization efforts. Revenue is projected at
The
What's particularly noteworthy is management's statement about achieving breakeven at historical revenue levels - indicating their cost structure has been meaningfully optimized. However, several indicators suggest vulnerability: the company's small market cap (
This preliminary report suggests Iridex is executing a financial stabilization strategy rather than pursuing aggressive growth. While the directional metrics are modestly positive, the magnitude of improvement remains , and external risks could easily impact performance.
MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the first quarter ended March 29, 2025.
First Quarter 2025 Results
- Total revenue is expected to be between
$11.8 million and$12.0 million , compared to$11.8 million in the comparable quarter of 2024 - Sold approximately 13,900 Cyclo G6 probes, compared to 13,300 in the prior year quarter
- Sold approximately 24 Cyclo G6 Laser Systems, compared to 22 in the prior year quarter
- Cash and cash equivalents as of March 29, 2025 were
$7.2 million
President and CEO Patrick Mercer commented, "As announced last month, we are pre-announcing our first quarter results in order to highlight (i) the stabilization of our business and (ii) the Company’s improved financial condition following the strategic investment by Novel Inspiration International Co., Ltd. (“Novel”). We have delivered top line revenue increases versus the prior year in each of the last two quarters, even while significantly reducing operating expenses. We are exposed to external factors like changes in tariff policies, but we remain capable of achieving breakeven or better performance at historical revenue levels. On April 16, 2025, we will hold an investor call to introduce Iridex and Novel’s strategic vision for the Company."
These preliminary results are based on management’s initial analysis of operations for the quarter ended March 29, 2025, and are subject to further internal review, potential adjustments and review by the Company’s external auditors.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning financial and operating results. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2025. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Media Contact
Joan Stauffer
jstauffer@iridex.com
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
What are Iridex (IRIX) Q1 2025 revenue expectations?
How many Cyclo G6 probes did IRIX sell in Q1 2025?
What is Iridex's cash position as of March 2025?
How has Novel Inspiration's investment impacted IRIX's financial condition?
